Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticoagulation: new challenges, old drugs.

Brian Olshansky1

  • 1Department of Internal Medicine, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, 4426A JCP, Iowa City, IA 52242, USA. brian-olshansky@uiowa.edu

Current Cardiology Reports
|August 18, 2005
PubMed
Summary

Warfarin anticoagulation effectively prevents stroke in atrial fibrillation (AF) patients but is difficult to manage. Ximelagatran shows similar stroke prevention efficacy with potentially fewer complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What are we treating? The need for broader provider understanding of POTS, its nature, and care.

The American journal of medicine·2026
Same author

Indications, contraindications, and step-by-step methodology for performing carotid sinus massage in patients presenting with syncope : A scientific statement of an Ad Hoc Syncope Consortium endorsed by: the European Autonomic Society (EFAS), Gruppo Italiano Multidisciplinare Syncope (GIMSI) and European Geriatric Medicine Society (EuGMS).

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026
Same author

Clinical outcomes of rate control versus rhythm control as the initial strategy in atrial fibrillation: insights from the GLORIA-AF registry.

Internal and emergency medicine·2026
Same author

Rhythm Control in Patients With Recently Diagnosed Atrial Fibrillation: Findings From the GLORIA-AF Registry Phase III.

Journal of the American Heart Association·2026
Same author

Stylet-in-sheath: A new solution to an old problem?

Heart rhythm·2026
Same author

Sham-controlled trials and the future of electrophysiology: Reflections on SHAM-PFA.

Heart rhythm O2·2025

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis Research

Background:

  • Atrial fibrillation (AF) management necessitates rate control, rhythm maintenance, and anticoagulation to prevent thromboemboli.
  • Warfarin is effective for stroke prevention in high-risk AF patients but presents challenges in management.
  • Ideal anticoagulants offer fewer interactions, uniform dosing, no routine monitoring, and reduced bleeding risk.

Purpose of the Study:

  • To compare the efficacy and safety of fixed-dose ximelagatran with warfarin in AF patients.
  • To evaluate ximelagatran as a potential alternative to warfarin for stroke prevention.

Main Methods:

  • Two large randomized noninferiority trials were conducted.
  • Patients with AF at high risk for stroke were included.
  • Fixed-dose ximelagatran was compared against warfarin therapy.

Main Results:

  • Ximelagatran demonstrated noninferiority to warfarin in preventing stroke and thromboembolic events.
  • The intention-to-treat analysis indicated comparable efficacy between the two anticoagulants.
  • Long-term risk profiles suggested similar or potentially improved safety with ximelagatran.

Conclusions:

  • Ximelagatran is as effective as warfarin in preventing stroke and thromboembolic events in AF patients.
  • Ximelagatran may offer a favorable risk profile compared to warfarin.
  • The findings support ximelagatran as a viable alternative for anticoagulation in AF management.

Related Experiment Videos